Daratumumab in multiple myeloma

Daratumumab Plus Standard Therapy for Multiple Myeloma - NCI

Adding daratumumab (Darzalex) to standard VRD treatment helped people with newly diagnosed multiple myeloma live longer without their cancer ...

Darzalex (Daratumumab) | International Myeloma Foundation

How Does Darzalex Work? · It kills myeloma cells directly. · It recruits immune system cells called macrophages. · It recruits natural killer (NK) cells, which ...

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for ...

Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab ...

Daratumumab and its potential in the treatment of multiple myeloma

Daratumumab is a novel, high-affinity, therapeutic human monoclonal antibody against unique CD38 epitope with broad-spectrum killing activity. It has a ...

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone ...

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Outperforms VRd Alone for Multiple Myeloma ... (SAN DIEGO, Dec. ... At a median ...

FDA approves daratumumab and hyaluronidase-fihj with bortezomib ...

On July 30, 2024, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research ...

Daratumumab for patients with myeloma with early or late relapse ...

Although daratumumab is unable to fully overcome the adverse prognosis of early relapse, our results support the use of daratumumab for patients ...

Daratumumab: a game changer in myeloma therapy - The Lancet

Daratumumab is effective in all phases of therapy and might obviate the need for many transplantations. Appropriate clinical use of daratumumab will increase ...

Daratumumab: Dawn of a New Paradigm in Multiple Myeloma? - PMC

Daratumumab (Darzalex) is a first-in-class inhibitor of CD38 and the first monoclonal antibody approved for treatment of myeloma.

Overall Survival With Daratumumab, Lenalidomide, and ...

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.

Official Consumer Website | DARZALEX® & DARZALEX FASPRO ...

DARZALEX FASPRO® is a prescription medicine used to treat adult patients with multiple myeloma: ... It is not known if DARZALEX FASPRO® is safe and effective in ...

Addition of daratumumab to multiple myeloma backbone regimens ...

Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone ...

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than bortezomib and dexamethasone alone.

Multiple Myeloma Resources - darzalex faspro

Comprehensive resource dedicated to educating and supporting patients with multiple myeloma and their caregivers.

Daratumumab for Multiple Myeloma Improves Progression-Free ...

A summary of clinical trial results showing that daratumumab plus lenalidomide and dexamethasone improved progression-free survival for ...

Daratumumab monotherapy in patients with treatment-refractory ...

Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable ...

FDA approves daratumumab for multiple myeloma ineligible for ...

The Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with lenalidomide and dexamethasone for patients with ...

DARZALEX® (daratumumab)-SC based quadruplet regimen ...

Daratumumab is the only CD38-directed antibody approved to be given subcutaneously to treat patients with multiple myeloma. ... Daratumumab SC is ...

Clinical efficacy of daratumumab monotherapy in patients with ...

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. ,. J Immunol. ,. 2011. , ...

Evaluation of Daratumumab for the Treatment of Multiple Myeloma ...

This study suggests that incorporating daratumumab to backbone regimens may be associated with improved PFS among patients with newly diagnosed HRMM or ...